COGT Valuation

Cogent Biosciences Inc

Add to Watchlist

Advanced Chart

11.770

-0.095(-0.801%)1D

Overview
Forecast
Valuation
Earnings

COGT Relative Valuation

COGT's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, COGT is overvalued; if below, it's undervalued.

Historical Valuation

Cogent Biosciences Inc (COGT) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -4.79. The fair price of Cogent Biosciences Inc (COGT) is between to according to relative valuation methord.

Relative Value

Fair Zone

Current Price：11.77

Fair

-5.59

Trailing

Forward

-6.48

EV/EBITDA

Cogent Biosciences Inc. (COGT) has a current EV/EBITDA of -6.48. The 5-year average EV/EBITDA is -1.42. The thresholds are as follows: Strongly Undervalued below -5.21, Undervalued between -5.21 and -3.31, Fairly Valued between 0.47 and -3.31, Overvalued between 0.47 and 2.36, and Strongly Overvalued above 2.36. The current Forward EV/EBITDA of -6.48 falls within the Strongly Undervalued range.

-4.98

EV/EBIT

Cogent Biosciences Inc. (COGT) has a current EV/EBIT of -4.98. The 5-year average EV/EBIT is -2.98. The thresholds are as follows: Strongly Undervalued below -5.55, Undervalued between -5.55 and -4.26, Fairly Valued between -1.70 and -4.26, Overvalued between -1.70 and -0.41, and Strongly Overvalued above -0.41. The current Forward EV/EBIT of -4.98 falls within the Undervalued range.

0.00

Cogent Biosciences Inc. (COGT) has a current PS of 0.00. The 5-year average PS is 32693.74. The thresholds are as follows: Strongly Undervalued below -354468.87, Undervalued between -354468.87 and -160887.56, Fairly Valued between 226275.05 and -160887.56, Overvalued between 226275.05 and 419856.35, and Strongly Overvalued above 419856.35. The current Forward PS of 0.00 falls within the Historic Trend Line -Fairly Valued range.

-6.80

P/OCF

Cogent Biosciences Inc. (COGT) has a current P/OCF of -6.80. The 5-year average P/OCF is -5.08. The thresholds are as follows: Strongly Undervalued below -9.37, Undervalued between -9.37 and -7.22, Fairly Valued between -2.94 and -7.22, Overvalued between -2.94 and -0.80, and Strongly Overvalued above -0.80. The current Forward P/OCF of -6.80 falls within the Historic Trend Line -Fairly Valued range.

-9.18

P/FCF

Cogent Biosciences Inc. (COGT) has a current P/FCF of -9.18. The 5-year average P/FCF is -5.46. The thresholds are as follows: Strongly Undervalued below -15.09, Undervalued between -15.09 and -10.28, Fairly Valued between -0.64 and -10.28, Overvalued between -0.64 and 4.18, and Strongly Overvalued above 4.18. The current Forward P/FCF of -9.18 falls within the Historic Trend Line -Fairly Valued range.

Cogent Biosciences Inc (COGT) has a current Price-to-Book (P/B) ratio of 28.71. Compared to its 3-year average P/B ratio of 5.09 , the current P/B ratio is approximately 463.82% higher. Relative to its 5-year average P/B ratio of 3.64, the current P/B ratio is about 687.57% higher. Cogent Biosciences Inc (COGT) has a Forward Free Cash Flow (FCF) yield of approximately -14.28%. Compared to its 3-year average FCF yield of -19.85%, the current FCF yield is approximately -28.08% lower. Relative to its 5-year average FCF yield of -18.48% , the current FCF yield is about -22.77% lower.

28.71

P/B

Median3y

5.09

Median5y

3.64

-14.28

FCF Yield

Median3y

-19.85

Median5y

-18.48

Competitors Valuation Multiple

The average P/S ratio for COGT's competitors is 73.83, providing a benchmark for relative valuation. Cogent Biosciences Inc Corp (COGT) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

COGT.O

Cogent Biosciences Inc

Immunocore Holdings PLC

Celldex Therapeutics Inc

Twist Bioscience Corp

Aurinia Pharmaceuticals Inc

5.58

22.41%

1.59B

Performance Decomposition

Market capitalization of COGT increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of COGT in the past 1 year is driven by Unknown.